PIK3CA and colorectal carcinoma: There are other ongoing phase 1 trials in the treatment of CRC, evaluating alpelisib, capecitabine, and radiation in rectal cancer (NCT02550743) or alpelisib with capecitabine in mCRC with PIK3CA gene mutation (NCT04753203).